Perspective · 2016
Conference abstract
Efficacious dendritic cell-based immunotherapy for advanced multiple malignancies
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background & Aims: Dendritic cell (DC)-based immunotherapy is a promising viable tool in cancer treatment. Dendritic cell (DC)-based vaccination can provoke antitumor T cell responses in vivo. These case studies examined feasibility and outcome of DC-based tumor vaccination for patients with prostate cancer (n=5), breast cancer (n=2), cervical cancer (n=1), gastric cancer (n=1), pancreatic cancer (n=1) This approach has been used mostly in patients in the presence of defined tumor antigens. Experimental Design: Accessible tumor tissue was disrupted into single cell suspensions. Autologous DCs were prepared from adherent peripheral blood mononuclear cells and cultured in granulocyte macrophage colony-stimulating factor, interleukin and autologous plasma. Tumor cells and DCs were cocultured in the presence of polyethylene glycol to generate the fusions. Fusion cells were quantified by determining the percentage of cells that co-express tumor and DC markers. Patients vaccinated with three doses of DC (10Ã?Â?106) were administered after every 2 weeks intervals and assessed weekly for toxicity and tumor response was assessed at 3 months after completion of vaccination. Results: Vaccination was well tolerated. No physical signs of autoimmunity were detected. None of the patients was found to meet the criteria complete responses. There was no evidence of significant toxicity from vaccine or adjuvant. There was increased expression of T helper type 1 cytokines. Vaccination resulted in a significant reduction in the level of prostate-specific antigen (PSA) in prostate cancer patient. There was 20% regression of tumor load in one prostate cancer patient. One patient with prostate cancer had surgery followed by Immunotherapy. PET scan reveals no further cancerous activity was found. Disease was stable upto 6 months in case of breast and cervical cancer patients. Conclusion: DC-based vaccination can stimulate an antitumoral T cell response in patients with various cancers. These data indicate that vaccination with autologous tumor-pulsed DCs generated from peripheral blood is safe and can induce tumor-specific cellular cytotoxicity. Clinical responses are achievable, even in patients with advanced disease.
Keywords
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Short communication · 29 Nov 2024
Neoantigen Discovery and Dendritic Cell-based Vaccines in Lung Cancer Immunotherapy
Research article · 2 Feb 2015
Efficacy of dendritic cell-cytokine-induced killer immunotherapy plus intensity-modulated radiation therapy in treating elderly patients with esophageal carcinoma
Perspective · 30 Dec 2021
Cell-based Immunotherapies: Molecular Imaging Biomarkers
Review article · 2013
Stem Cell-based Therapies in Multiple Sclerosis
More from this journal
The newest in Biochemistry & Molecular Biology Journal.
Article · 17 Aug 2026
The Role of Human Tumor Necrosis Factor-andalpha; (TNF-andalpha;) in Predicting Diabetic Nephropathy in Type ? Diabetic Patients
Article · 21 May 2026
Kinetic Perspectives on Enzyme-Catalyzed Reactions in Biological Systems
Article · 21 May 2026
Structural Pathways and Stability in Protein Folding
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalBiochemistry & Molecular Biology Journal
- SubjectBiochemistry & Biotechnology
- SubjectGenetics & Molecular Biology
- BylineArticles whose byline prints “Chandan R Bora”
- BylineArticles whose byline prints “Pramod Dhembare”
